Upadacitinib Oral Solution(AbbVie)
Tier C — Watch / tradeUpadacitinib Oral Solution(AbbVie)
Targets：JAK1
Brand：RINVOQ LQ, Rinvoq Lq, RINVOQ® LQ
Indications (approved)：Non-radiographic axial spondyloarthritis, Crohn's disease, Ulcerative colitis, Rheumatoid arthritis, Ankylosing spondylitis, Atopic dermatitis, 系统性少年特发性关节炎, Psoriatic arthritis
Regional status
Synthetic routes & intermediates
Frequently asked questions
What are the approved indications of Upadacitinib Oral Solution(AbbVie)?
Approved indications include: Non-radiographic axial spondyloarthritis, Crohn's disease, Ulcerative colitis, Rheumatoid arthritis, Ankylosing spondylitis, Atopic dermatitis, 系统性少年特发性关节炎, Psoriatic arthritis.
When does the Upadacitinib Oral Solution(AbbVie) patent expire?
No public expiry year is available for Upadacitinib Oral Solution(AbbVie) yet; this page updates once verified.
How do I get a quote for Upadacitinib Oral Solution(AbbVie) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27